Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/BCL2L1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/BCL2L1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/BCL2L1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/BCL2L1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/BCL2L1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/BCL2L1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/BCL2L1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/BCL2L1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:200123611 | Stomach | CAG with IM | regulation of extrinsic apoptotic signaling pathway | 24/1050 | 151/18723 | 3.58e-06 | 1.41e-04 | 24 |
GO:004440311 | Stomach | CAG with IM | biological process involved in symbiotic interaction | 36/1050 | 290/18723 | 6.58e-06 | 2.40e-04 | 36 |
GO:200124311 | Stomach | CAG with IM | negative regulation of intrinsic apoptotic signaling pathway | 18/1050 | 98/18723 | 7.52e-06 | 2.65e-04 | 18 |
GO:000183611 | Stomach | CAG with IM | release of cytochrome c from mitochondria | 13/1050 | 59/18723 | 1.83e-05 | 5.63e-04 | 13 |
GO:190357311 | Stomach | CAG with IM | negative regulation of response to endoplasmic reticulum stress | 11/1050 | 44/18723 | 2.27e-05 | 6.54e-04 | 11 |
GO:001082111 | Stomach | CAG with IM | regulation of mitochondrion organization | 21/1050 | 144/18723 | 5.35e-05 | 1.36e-03 | 21 |
GO:001082311 | Stomach | CAG with IM | negative regulation of mitochondrion organization | 11/1050 | 49/18723 | 6.66e-05 | 1.62e-03 | 11 |
GO:005170111 | Stomach | CAG with IM | biological process involved in interaction with host | 26/1050 | 203/18723 | 7.20e-05 | 1.74e-03 | 26 |
GO:000700611 | Stomach | CAG with IM | mitochondrial membrane organization | 18/1050 | 116/18723 | 7.92e-05 | 1.86e-03 | 18 |
GO:190165411 | Stomach | CAG with IM | response to ketone | 25/1050 | 194/18723 | 8.90e-05 | 2.04e-03 | 25 |
GO:200123711 | Stomach | CAG with IM | negative regulation of extrinsic apoptotic signaling pathway | 16/1050 | 97/18723 | 9.27e-05 | 2.11e-03 | 16 |
GO:001063911 | Stomach | CAG with IM | negative regulation of organelle organization | 37/1050 | 348/18723 | 1.45e-04 | 2.89e-03 | 37 |
GO:004690211 | Stomach | CAG with IM | regulation of mitochondrial membrane permeability | 12/1050 | 63/18723 | 1.70e-04 | 3.28e-03 | 12 |
GO:00086251 | Stomach | CAG with IM | extrinsic apoptotic signaling pathway via death domain receptors | 14/1050 | 82/18723 | 1.72e-04 | 3.30e-03 | 14 |
GO:00093141 | Stomach | CAG with IM | response to radiation | 44/1050 | 456/18723 | 3.24e-04 | 5.39e-03 | 44 |
GO:19020411 | Stomach | CAG with IM | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 10/1050 | 49/18723 | 3.27e-04 | 5.39e-03 | 10 |
GO:190223611 | Stomach | CAG with IM | negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway | 6/1050 | 20/18723 | 6.02e-04 | 8.74e-03 | 6 |
GO:190589711 | Stomach | CAG with IM | regulation of response to endoplasmic reticulum stress | 13/1050 | 82/18723 | 6.10e-04 | 8.79e-03 | 13 |
GO:005188111 | Stomach | CAG with IM | regulation of mitochondrial membrane potential | 12/1050 | 74/18723 | 7.94e-04 | 1.07e-02 | 12 |
GO:007058411 | Stomach | CAG with IM | mitochondrion morphogenesis | 6/1050 | 21/18723 | 8.03e-04 | 1.08e-02 | 6 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa05170 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa05220 | Colorectum | AD | Chronic myeloid leukemia | 31/2092 | 76/8465 | 1.41e-03 | 8.46e-03 | 5.39e-03 | 31 |
hsa05225 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa04137 | Colorectum | AD | Mitophagy - animal | 29/2092 | 72/8465 | 2.49e-03 | 1.35e-02 | 8.59e-03 | 29 |
hsa05166 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa01521 | Colorectum | AD | EGFR tyrosine kinase inhibitor resistance | 29/2092 | 79/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 29 |
hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa054171 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa051701 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa052201 | Colorectum | AD | Chronic myeloid leukemia | 31/2092 | 76/8465 | 1.41e-03 | 8.46e-03 | 5.39e-03 | 31 |
hsa052251 | Colorectum | AD | Hepatocellular carcinoma | 59/2092 | 168/8465 | 1.50e-03 | 8.69e-03 | 5.54e-03 | 59 |
hsa041371 | Colorectum | AD | Mitophagy - animal | 29/2092 | 72/8465 | 2.49e-03 | 1.35e-02 | 8.59e-03 | 29 |
hsa051661 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa015211 | Colorectum | AD | EGFR tyrosine kinase inhibitor resistance | 29/2092 | 79/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 29 |
hsa050124 | Colorectum | MSS | Parkinson disease | 140/1875 | 266/8465 | 2.32e-28 | 7.79e-26 | 4.77e-26 | 140 |
hsa050224 | Colorectum | MSS | Pathways of neurodegeneration - multiple diseases | 192/1875 | 476/8465 | 2.79e-20 | 1.04e-18 | 6.36e-19 | 192 |
hsa050144 | Colorectum | MSS | Amyotrophic lateral sclerosis | 156/1875 | 364/8465 | 1.43e-19 | 4.62e-18 | 2.83e-18 | 156 |
hsa051314 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Indole-based analog 2 | | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | NAVITOCLAX, ABT-263 | | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | antagonist | 252166532 | ABT 737 | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | PMID27744724-Compound-26 | | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | GOSSYPOL | GOSSYPOL | 19555126 |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | antagonist | 252166530 | VENETOCLAX | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | APG-1252 | | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | ABT-737 | ABT 737 | 22386982,22747598 |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | ABT-263 | NAVITOCLAX | |
598 | BCL2L1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | inhibitor | CHEMBL443684 | NAVITOCLAX | |